<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213876</url>
  </required_header>
  <id_info>
    <org_study_id>3154</org_study_id>
    <nct_id>NCT00213876</nct_id>
  </id_info>
  <brief_title>Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours</brief_title>
  <official_title>Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <brief_summary>
    <textblock>
      At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria
      in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are
      characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This
      benign histological subtype relapses in few cases with a more aggressive histology. To
      determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004.
      Then, our study was designed to identify diagnostic molecular and metabolic markers that
      could eventually be used as a signature characterising grade A versus grade B
      oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping
      study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression
      and immunohistochemistry, since the metabolic study will be the spectroscopic examination of
      in vivo tumour. This study will include paediatric and adult patients followed for
      oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures.
      All these results will be correlated to survival and clinical features.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">189</enrollment>
  <condition>Oligodendrogliomas</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with oligodendroglioma or medulloblastoma or glioma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Paediatric and adult patients (&gt; 1 year of age)

          -  Patient with oligodendroglioma or medulloblastoma or glioma

          -  Possibility of 3 year follow-up

          -  Patient consent obtained

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natacha Entz-Werle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Natacha Entz-Werle</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>August 29, 2011</last_update_submitted>
  <last_update_submitted_qc>August 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2011</last_update_posted>
  <keyword>Brain tumours</keyword>
  <keyword>oligodendrogliomas</keyword>
  <keyword>allelotyping</keyword>
  <keyword>SAGE</keyword>
  <keyword>Presence of molecular abnormalities statistically linked to survival or response to chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

